StreetInsider.com News Articles

TD Cowen Assumes Agios Pharma (AGIO) at Buy

Sat, 22 Aug 2026 07:55:17 -0400

TD Cowen analyst Jon Thome assumes coverage on Agios Pharma (NASDAQ: AGIO) with a Buy rating.

For an analyst ratings summary and ratings history on Agios Pharma click here. For more ratings news on Agios Pharma click here.

Shares of Agios Pharma closed at $33.09 yesterday.

Agios Pharma (AGIO) Reiterated at Overweight by Cantor Fitzgerald on Thalassemia Opportunity

Mon, 17 Aug 2026 07:54:11 -0400

Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating on Agios Pharma (NASDAQ: AGIO).

The analyst commented, "The FDA granted mitapivat's sNDA priority review and indicated to Agios that there is no need for an AdComm. Yet despite a seemingly high probability of approval in a sizable rare-disease indication that features very substantial unmet need, few investors appear willing to give AGIO much, if any, value for this opportunity. AGIO trades with an EV of just ~$1B. We think this valuation is fully supported by mitapivat's thalassemia opportunity, which we estimate at ~$500M in the US and ~$800M worldwide. Recall, Agios

Agios Pharma (AGIO) PT Raised to $34 at JPMorgan

Fri, 07 Aug 2026 08:57:04 -0400

JPMorgan analyst Tessa Romero raised the price target on Agios Pharma (NASDAQ: AGIO) to $34.00 (from $31.00) while maintaining a Neutral rating.

Form 4 AGIOS PHARMACEUTICALS, For: Aug 04 Filed by: Gheuens Sarah

Thu, 06 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260806/26884174.html

Form 4 AGIOS PHARMACEUTICALS, For: Aug 04 Filed by: Gheuens Sarah

Thu, 06 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260806/26884174.html

Form 144 AGIOS PHARMACEUTICALS, Filed by: Gheuens Sarah

Tue, 04 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260804/26866284.html

Form 144 AGIOS PHARMACEUTICALS, Filed by: Gheuens Sarah

Tue, 04 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260804/26866284.html

Form SCHEDULE 13G/A AGIOS PHARMACEUTICALS, Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.

Mon, 03 Aug 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260803/26854496.html

Form SCHEDULE 13G/A AGIOS PHARMACEUTICALS, Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.

Mon, 03 Aug 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260803/26854496.html

Agios Pharma (AGIO) PT Lowered to $39 at Truist Securities

Fri, 31 Jul 2026 07:09:26 -0400

Truist Securities analyst Greg Renza lowered the price target on Agios Pharma (NASDAQ: AGIO) to $39.00 (from $41.00) while maintaining a Buy rating.

Form 10-Q AGIOS PHARMACEUTICALS, For: Jun 30

Thu, 30 Jul 2026 09:56:00 -0400

si-local-file:///var/storage/secattach/20260730/26840623.html

Form 10-Q AGIOS PHARMACEUTICALS, For: Jun 30

Thu, 30 Jul 2026 09:56:00 -0400

si-local-file:///var/storage/secattach/20260730/26840623.html

Agios Pharma (AGIO) Misses Q2 EPS by 4c

Thu, 30 Jul 2026 06:33:37 -0400

Agios Pharma (NASDAQ: AGIO) reported Q2 EPS of ($1.69), $0.04 worse than the analyst estimate of ($1.65). Revenue for the quarter came in at $44.74 million versus the consensus estimate of $26.57 million.

For earnings history and earnings-related data on Agios Pharma (AGIO) click here.

Form 8-K AGIOS PHARMACEUTICALS, For: Jul 30

Thu, 30 Jul 2026 06:33:00 -0400

si-local-file:///var/storage/secattach/20260730/26838104.html

Form 8-K AGIOS PHARMACEUTICALS, For: Jul 30

Thu, 30 Jul 2026 06:33:00 -0400

si-local-file:///var/storage/secattach/20260730/26838104.html

Agios Reports Second Quarter 2026 Financial Results and Provides Business Update